North American Star Consortium

/ ABSTRACT This administrative supplement request seeks continued support for the Early Therapeutics Clinical Trials Network (ETCTN) UM1 North American Star Consortium (NASC), led by the Princess Margaret Cancer Centre (LAO) with partnering Academic Organizations including the Moffitt Cancer Center (MCC), Virginia Commonwealth University (VCU), Northwestern University (NWU), the University of Texas Southwestern (UTSW), the Rutgers Cancer Institute of New Jersey (CINJ), and the Sylvester Comprehensive Cancer Center (SCCC). Due to the delayed publication of the new ETCTN Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) has advised that current UM1 sites may request a 12-month extension with funds to maintain critical clinical research operations. During the extension period, NASC will continue executing early-phase therapeutic clinical trials, supporting patient accrual, ensuring high-quality biospecimen collection for protocol-mandated analyses, and sustaining essential scientific and administrative infrastructure. This supplement will permit uninterrupted operation of ETCTN trials across NASC institutions, ensuring continuity of early-phase drug development efforts that are central to the mission of the ETCTN and aligned with the scientific scope of the parent award. Project Number: 3UM1CA186644-09S1 | Fiscal Year: 2026 | NIH Institute/Center: National Cancer Institute (NCI) | Principal Investigator: Philippe Bedard (+7 co-PIs) | Institution: UNIVERSITY HEALTH NETWORK, TORONTO, ON | Award Amount: $1,770,712 | Activity Code: UM1 View on NIH RePORTER: https://reporter.nih.gov/project-details/11495520